Bloodstream Infections Caused by Carbapenem-Resistant Enterobacterales: Risk Factors for Mortality, Antimicrobial Therapy and Treatment Outcomes from a Prospective Multicenter Study

References

• Shrivastava SRL, Shrivastava PS, Ramasamy J . World health organization releases global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. J Med Soc. 2018;32(1):76. doi:10.4103/jms.jms_25_17
   Google Scholar
• Zhang Y, Wang Q, Yin Y, et al. Epidemiology of carbapenem-resistant Enterobacteriaceae infections: report from the China CRE network. Antimicrob Agents Chemother. 2018;62. doi:10.1128/aac.01882-17
   Web of Science ®Google Scholar
• Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis. 2011;53:60–67. doi:10.1093/cid/cir20221653305
   PubMed Web of Science ®Google Scholar
• Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis. 2011;17:1791. doi:10.3201/eid1710.11065522000347
   PubMed Web of Science ®Google Scholar
• Gajdács M, Burián K, Terhes G. Resistance levels and epidemiology of non-fermenting gram-negative bacteria in urinary tract infections of inpatients and outpatients (RENFUTI): A 10-year epidemiological snapshot. Antibiotics. 2019;8:143. doi:10.3390/antibiotics8030143
   Web of Science ®Google Scholar
• David S, Reuter S, Harris SR, et al. Epidemic of carbapenem-resistant Klebsiella pneumoniae in Europe is driven by nosocomial spread. Nat Microbiol. 2019;4:1919–1929. doi:10.1038/s41564-019-0492-831358985
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Trecarichi EM, De Rosa FG, et al. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother. 2015;70:2133–2143. doi:10.1093/jac/dkv08625900159
   PubMed Web of Science ®Google Scholar
• Grégoire N, Aranzana-Climent V, Magréault S, Marchand S, Couet W. Clinical pharmacokinetics and pharmacodynamics of colistin. Clin Pharmacokinet. 2017;56:1441–1460. doi:10.1007/s40262-017-0561-128550595
   PubMed Web of Science ®Google Scholar
• Jackson J, Chen C, Buising K. Aminoglycosides: how should we use them in the 21st century? Curr Opin Infect Dis. 2013;26:516–525. doi:10.1097/qco.000000000000001224141453
   PubMed Web of Science ®Google Scholar
• Wang J, Pan Y, Shen J, Xu Y. The efficacy and safety of tigecycline for the treatment of bloodstream infections: a systematic review and meta-analysis. Ann Clin Microbiol Antimicrob. 2017;16:24. doi:10.1186/s12941-017-0199-828381268
   PubMed Web of Science ®Google Scholar
• Gajdács M. The concept of an ideal antibiotic: implications for drug design. Molecules. 2019;24:892. doi:10.3390/molecules24050892
   PubMed Web of Science ®Google Scholar
• Gajdács M, Albericio F. Antibiotic resistance: from the bench to patients. Antibiotics. 2019;8:129. doi:10.3390/antibiotics8030129
   Web of Science ®Google Scholar
• Seo H, Lee SC, Chung H, et al. Clinical and Microbiological Analysis of Risk Factors for Mortality in Patients with Carbapenem-Resistant Enterobacteriaceae Bacteremia. Int J Antimicrob Agents. 2020;56(4):106126. doi:10.1016/j.ijantimicag.2020.106126.
   Google Scholar
• Zavascki AP, Barth AL, Fernandes JF, Moro AL, Gonçalves AL, Goldani LZ. Reappraisal of Pseudomonas aeruginosa hospital-acquired pneumonia mortality in the era of metallo-beta-lactamase-mediated multidrug resistance: a prospective observational study. Crit Care. 2006;10:R114. doi:10.1186/cc500616882337
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis. 2017;17:726–734. doi:10.1016/s1473-3099(17)30228-128442293
   PubMed Web of Science ®Google Scholar
• Daikos GL, Tsaousi S, Tzouvelekis LS, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother. 2014;58:2322–2328. doi:10.1128/aac.02166-1324514083
   PubMed Web of Science ®Google Scholar
• Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801–810. doi:10.1001/jama.2016.028726903338
   PubMed Web of Science ®Google Scholar
• Wang X, Wang Q, Cao B, et al. Retrospective observational study from a chinese network of the impact of combination therapy versus monotherapy on mortality from carbapenem-resistant enterobacteriaceae bacteremia. Antimicrob Agents Chemother. 2019;63. doi:10.1128/aac.01511-18
   Web of Science ®Google Scholar
• Zhang Y, Li Y, Zeng J, et al. Risk factors for mortality of inpatients with Pseudomonas aeruginosa bacteremia in China: impact of resistance profile in the mortality. Infect Drug Resist. 2020;13::4115–4123. doi:10.2147/IDR.S268744
   Web of Science ®Google Scholar
• Cecconi M, Evans L, Levy M, Rhodes A. Sepsis and septic shock. Lancet. 2018;392:75–87. doi:10.1016/s0140-6736(18)30696-229937192
   PubMed Web of Science ®Google Scholar
• Li Y, Li J, Hu T, et al. Five-year change of prevalence and risk factors for infection and mortality of carbapenem-resistant Klebsiella pneumoniae bloodstream infection in a tertiary hospital in North China. Antimicrob Resist Infect Control. 2020;9:79. doi:10.1186/s13756-020-00728-332487221
   PubMed Web of Science ®Google Scholar
• Trecarichi EM, Tumbarello M. Therapeutic options for carbapenem-resistant Enterobacteriaceae infections. Virulence. 2017;8:470–484. doi:10.1080/21505594.2017.129219628276996
   PubMed Web of Science ®Google Scholar
• Zhou K, Xiao T, David S, et al. Novel subclone of carbapenem-resistant klebsiella pneumoniae sequence type 11 with enhanced virulence and transmissibility, China. Emerg Infect Dis. 2020;26:289–297. doi:10.3201/eid2602.19059431961299
   PubMed Web of Science ®Google Scholar
• Pournaras S, Vrioni G, Neou E, et al. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay. Int J Antimicrob Agents. 2011;37(3):244-7. doi:10.1016/j.ijantimicag.2010.10.031.
   Google Scholar
• Kumar A, Zarychanski R, Light B, et al. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med. 2010;38:1773–1785. doi:10.1097/CCM.0b013e3181eb3ccd20639750
   PubMed Web of Science ®Google Scholar
• Vallés J, Rello J, Ochagavía A, Garnacho J, Alcalá MA. Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival. Chest. 2003;123:1615–1624. doi:10.1378/chest.123.5.161512740282
   PubMed Web of Science ®Google Scholar
• Yahav D, Lador A, Paul M, Leibovici L. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother. 2011;66:1963–1971. doi:10.1093/jac/dkr24221685488
   PubMed Web of Science ®Google Scholar
• Tasina E, Haidich AB, Kokkali S, Arvanitidou M. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis. 2011;11:834–844. doi:10.1016/s1473-3099(11)70177-321784708
   PubMed Web of Science ®Google Scholar
• De Pascale G, Montini L, Pennisi M, et al. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Crit Care. 2014;18:R90. doi:10.1186/cc1385824887101
   PubMed Web of Science ®Google Scholar
• Yang YS, Chen HY, Hsu WJ, et al. Overexpression of AdeABC efflux pump associated with tigecycline resistance in clinical Acinetobacter nosocomialis isolates. Clin Microbiol Infect. 2019;25:512.e1–512.e6. doi:10.1016/j.cmi.2018.06.012
   Web of Science ®Google Scholar
• Donadu MG, Trong LN, Ho D V, et al. Phytochemical compositions and biological activities of essential oils from the leaves, rhizomes and whole plant of hornstedtia bella škorničk. Antibiotics. 2020;9:334. doi:10.3390/antibiotics9060334
   Web of Science ®Google Scholar
• Fine DH, Furgang D, McKiernan M, et al. An investigation of the effect of an essential oil mouthrinse on induced bacteraemia: a pilot study. J Clin Periodontol. 2010;37::840–7. doi:10.1111/j.1600-051X.2010.01599.x
   Web of Science ®Google Scholar
• Zusman O, Altunin S, Koppel F, Dishon Benattar Y, Gedik H, Paul M. Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis. J Antimicrob Chemother. 2017;72:29–39. doi:10.1093/jac/dkw37727624572
   PubMed Web of Science ®Google Scholar
• Chotiprasitsakul D, Han JH, Cosgrove SE, et al. Comparing the outcomes of adults with enterobacteriaceae bacteremia receiving short-course versus prolonged-course antibiotic therapy in a multicenter, propensity score-matched cohort. Clin Infect Dis. 2018;66:172–177. doi:10.1093/cid/cix76729190320
   PubMed Web of Science ®Google Scholar
• Tansarli GS, Andreatos N, Pliakos EE, Mylonakis E. A systematic review and meta-analysis of antibiotic treatment duration for bacteremia due to enterobacteriaceae. Antimicrob Agents Chemother. 2019;63. doi: 10.1128/aac.02495-18.
   Web of Science ®Google Scholar